Contribute Try STAT+ Today

For the past few weeks, a U.S. bankruptcy court has heard objections to a plan to transform Purdue Pharma into a public benefit company, which would be run on behalf of the numerous communities that have pursued the drug maker for compensation for the cost of the opioid crisis.

The notion is part of an $8.3 billion settlement of criminal and civil charges reached with the Department of Justice. And at a recent hearing, U.S. Bankruptcy Court Judge Robert Drain cited a new book by an historian to express tentative support for the proposal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.